Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

OncoAlert and ecancer ASCO roundup - Day 1

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 1 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC

Dr Joshua Sabari and Dr Anna Minchom
Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC ( Dr Joshua Sabari and Dr Anna Minchom )
8 Jun 2021

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC

Dr Jonathan Spicer - McGill University, Montreal, Canada
NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC ( Dr Jonathan Spicer - McGill University, Montreal, Canada )
4 Jun 2021

ASCO 2021: Latest on PARPi and other treatments for mCRPC

Dr Neal Shore and Prof Oliver Sartor
ASCO 2021: Latest on PARPi and other treatments for mCRPC ( Dr Neal Shore and Prof Oliver Sartor )
4 Jun 2021

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma

Dr Terence Friedlander - UCSF, San Francisco, USA
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma ( Dr Terence Friedlander - UCSF, San Francisco, USA )
4 Jun 2021

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC

Dr Ian Chau - The Royal Marsden, London, UK
Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC ( Dr Ian Chau -  The Royal Marsden, London, UK )
4 Jun 2021

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
4 Jun 2021

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma

Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
4 Jun 2021

Rare inherited pathogenic germline variants observed in sporadic paediatric neuroblastoma cases

Dr Emily Blauel - Children’s Hospital of Philadelphia, Philadelphia, USA
Rare inherited pathogenic germline variants observed in sporadic paediatric neuroblastoma cases ( Dr Emily Blauel - Children’s Hospital of Philadelphia, Philadelphia, USA )
11 May 2021

PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer

Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France
PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer ( Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France )
4 May 2021

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours

Dr Matthew Marx - Mirati Therapeutics, San Diego, USA
MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours ( Dr Matthew Marx - Mirati Therapeutics, San Diego, USA )
30 Apr 2021

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA
Mechanisms of acquired resistance to KRAS G12C inhibition in cancer ( Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA )
26 Apr 2021